in this study granulocyte-macrophage colony stimulating factor (csf) was prepared from rabbit and guinea pig lung tissues. the biological activity of these csfs was measured on semisolid agar culture and compared with those of mouse and rat. weight of animals, incubation time and cross-reactivity of csfs with different bone marrow sources were also investigated. the results showed that both rab...

We successfully treated 3 consecutive patients who had nonneutropenic rhinocerebral zygomycosis, by use of subcutaneous granulocyte-macrophage colony-stimulating factor therapy combined with traditional surgical and medical treatment. All patients are currently free of disease. Granulocyte-macrophage colony-stimulating factor should be considered as adjuvant therapy for rhinocerebral zygomycosi...

conclusions the present study showed that g-csf is not superior to placebo in production of protective antibody titers after hbv vaccination but could result in a more rapid antibody response, compared to the placebo. results there was no statistically significant difference between anti-hbv antibody titers in patients receiving double dose hbv vaccination plus g-csf and patients receiving doub...

background: immunotoxins are comprised of both the cell targeting and the cell killing moieties. we previously established a new immunotoxin, i.e. shiga toxin granulocyte macrophage-colony stimulating factor (stxa1-gm-csf), comprises of catalytic domain of stx, as a killing moiety and gm-csf, as a cell targeting moiety. in this study, the ability of the immunotoxin to induce apoptosis and doubl...

In the background section of their abstract, Woei-Cherng Shyu and associates state that because granulocyte colony-stimulating factor (G-CSF) has anti-inflammatory and neuroprotective properties and the capacity to mobilize stem cells, it has the potential to be used in treatment of stroke. However, there are limited data about the effects of G-CSF on hemostasis. It has been suggested that G-CS...